{"id":63394,"date":"2026-05-11T10:22:12","date_gmt":"2026-05-11T10:22:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/63394\/"},"modified":"2026-05-11T10:22:12","modified_gmt":"2026-05-11T10:22:12","slug":"novartis-expands-india-role-in-global-drug-development","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/63394\/","title":{"rendered":"Novartis expands India role in global drug development"},"content":{"rendered":"

Novartis<\/a> is sharpening its India strategy as a pure-play innovator focused on core therapy areas such as cardiovascular disease, oncology and immunology after divesting its stake in its listed arm earlier this year.<\/p>\n

Speaking to Times of India, Novartis India<\/a> country president and managing director Amitabh Dube<\/a> said India is increasingly contributing to nearly every molecule the company commercialises globally and is moving up the value chain with early-stage scientific discovery and Phase I studies beginning to take shape in the country.
In February, Novartis announced the sale of its 71% stake in listed subsidiary Novartis India for around Rs 1,446 crore to private equity investors led by ChrysCapital. The company retained its unlisted arm, Novartis Healthcare<\/a>, to drive its innovative medicines business in India.<\/p>\n

Dube told TOI that Novartis recently initiated Phase I clinical research in Ahmedabad and will continue Phase II and III programmes across key therapeutic areas. He added that India played a major role in several global therapies, including Coartem Baby, cardiovascular drug Inclisiran (Sybrava), and prostate cancer therapy Pluvicto.<\/p>\n

Novartis operates one of its three global development hubs in India, alongside Basel and the US, with centres in Hyderabad and Mumbai.<\/p>\n

\"ETLive Events
\u201cOur philosophy has been to transform into a pure-play innovative medicines company,\u201d Dube told TOI, adding that Novartis remains committed to India with over 9,000 employees and plans to launch more new molecules in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis is sharpening its India strategy as a pure-play innovator focused on core therapy areas such as cardiovascular…\n","protected":false},"author":2,"featured_media":63395,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[17479,206,10088,9922,34697],"class_list":{"0":"post-63394","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-amitabh-dube","9":"tag-novartis","10":"tag-novartis-healthcare","11":"tag-novartis-india","12":"tag-novartis-india-expansion"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116555451361785634","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/63394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=63394"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/63394\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/63395"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=63394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=63394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=63394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}